Shijiazhuang Yiling Pharmaceutical (002603) Stock Price, Fundamentals & Analysis

What 002603 does

Shijiazhuang Yiling Pharmaceutical (002603) is a stock listed on the Shenzhen Stock Exchange in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. The company researches, produces, and sells traditional Chinese medicine (TCM) products in China and internationally. Its portfolio includes dietary supplements, healthy food and drinks, patent TCM products for respiratory health, cardiovascular disease, diabetes mellitus, oncology, urologic disease, sleep improvement, and anti-aging, as well as disinfection and personal protective equipment products and TCM formula granules. Founded in 1992 and headquartered in Shijiazhuang, China, it employs 11,343 people.

Key numbers explained

• The current price is 15.14 CNY, down 2.07% today.
• The trailing P/E ratio of 18.7 shows how much investors pay per 0.81 CNY of the last twelve months' earnings.
• The forward P/E ratio of 13.9 uses expected future earnings, often seen as a more optimistic gauge.
• The dividend yield of 5.28% means the company paid out 97% of its earnings as dividends, with the next ex-dividend date on 16 iun. 2026.
• The beta of 0.41 indicates the stock has historically moved less than the overall market.
• The 52-week range of 14.22 – 21.58 shows the price has moved -4.6% over the past year.
• The price-to-book ratio of 2.32 compares the market price to the company's book value per share.
• The debt-to-equity ratio of 0.2 (or 0,2 in Romanian formatting) signals a conservative capital structure with low leverage.

What to watch

Shijiazhuang Yiling Pharmaceutical (002603) operates in the Healthcare sector, where regulatory changes, drug approval cycles, and public health trends can affect demand for TCM products. As a Shenzhen Stock Exchange stock, it is part of the broader Chinese equity market, where currency movements and policy shifts often influence valuations. Investors in this space commonly compare it with peers such as Yunnan Baiyao Group (000538) and Hualan Biological Engineering (002007), which also operate in healthcare and biologics. The company's revenue of 7.87 mld. CNY and a -2.8% year-over-year growth rate are worth monitoring for top-line momentum. Its operating margin of 24.2% and profit margin of 17.5% reflect the efficiency of its business model, while the low beta of 0.41 suggests it may behave defensively during market swings.